
PAVmed fell 84.8% from $11.52 to $1.75, behind the S&P 500's +11.2%. Its worst day was Oct 1 (−28.7%), and its low came Nov 12 at $1.31.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
PAVmed closed at its highest level of the year, 4.6% above where the year started.
+94.7%, the year's best day, on 55M shares, the year's heaviest volume · S&P 500 +1.2%
Story events cover the past 12 months · Times ET
EPS of $-1.05 beat the $-4.62 estimate on $52,000.00 revenue (est. $25,000.00).
+13.0% · S&P 500 −0.3%
EPS of $-1.17 missed the $-0.71 estimate on $22,000.00 revenue (est. $79,200.00).
+0.6% · S&P 500 −1.2%
EPS of $-0.27 beat the $-0.64 estimate on $33,000.00 revenue (est. $48,000.00).
+9.7% · S&P 500 −0.2%
PAVmed shares fell 28.7%, while the S&P 500 rose 0.2%.
−28.7%, the year's worst day · S&P 500 +0.2%
EPS of $-0.19 beat the $-0.73 estimate on $41,000.00 revenue (est. $25,000.00).
+24.4% · S&P 500 −0.4%
Where it ended: a close of $1.75 on Nov 16, 2026.
Nothing in the past 12 months.
All PAVM dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for PAVM and SPY from Benzinga historical bars. Not investment advice.